Quality of Life and Its Contributing Factors in Patients with Familial Hypercholesterolaemia in Malaysia

Salmi Razali, Zaliha Ismail, Yung An Chua, Hapizah M Nawawi


Familial hypercholesterolaemia (FH) causes severe complications including cardiovascular diseases (CVDs) and stroke, leading to poor quality of life (QoL). Despite the availability of advanced treatment, data on QoL and its contributing factors is sparse. Hence, this study aimed to describe the pattern of QoL among FH patients and investigate its association with sociodemographic factors and illness characteristics. Hundred FH patients were assessed using Pro forma questionnaires and World Health Organization QoL questionnaire (WHOQOL-BREF). Significant contributing factors including the level of education, income, and the presence and type of CVDs. These findings may help to inform more effective interventions for FH patients.   

eISSN: 2398-4287© 2019. The Authors. Published for AMER ABRA cE-Bsby e-International Publishing House, Ltd., UK. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Peer–review under responsibility of AMER (Association of Malaysian Environment-Behaviour Researchers), ABRA (Association of Behavioural Researchers on Asians) and cE-Bs (Centre for Environment-Behaviour Studies), Faculty of Architecture, Planning & Surveying, UniversitiTeknologi MARA, Malaysia.


Familial hypercholesterolaemia; quality of life; sociodemography; cardiovascular disease

Full Text:



Al-Khateeb, A. R. (2016). Genetic researches among Malaysian familial hypercholesterolaemic population. Journal of the University of Malaya Medical Centre, 19(2).

Alonso, R., Mata, N., & Mata, P. (2005). Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opinion on Drug Safety, 4(2), 171-181.

Bandar, N. F. A., Jani, R., & Karim, M. A. (2014). Psychometric properties of the WHOQOL-BREF questionnaire among disabled students in Malaysian higher learning institutions. Applied Research in Quality of Life, 9(3), 469-478.

De Jongh, S., Kerckhoffs, M., Grootenhuis, M., Bakker, H., Heymans, H., & Last, B. (2003). Quality of life, anxiety and concerns among statin‐treated children with familial hypercholesterolaemia and their parents. Acta Paediatrica, 92(9), 1096-1101.

Diener, E., & Seligman, M. E. (2018). Beyond money: Progress on an economy of well-being. Perspectives on Psychological Science, 13(2), 171-175.

Galdas, P. M., Cheater, F., & Marshall, P. (2005). Men and health help‐seeking behaviour: literature review. Journal of Advanced Nursing, 49(6), 616-623.

Hagger, M.S., Hardcastle, S.J., Hu M, Kwok, S, Lin J, Nawawi, H.M., Pang, J, Santos, R.D., Soran, H., Su TC, Tomlinson, B, Watts, G.F. (2018a) Effects of Medication, Treatment, and Behavioral Beliefs on Intentions to Take Medication in Patients with Familial Hypercholesterolemia. Atherosclerosis for the FH special issue, Atherosclerosis.;277:493-501.

Hagger, M. S., Hardcastle, S. J., Hu, M., Kwok, S., Lin, J., Nawawi, H. M., et al. (2018b). Health literacy in familial hypercholesterolemia: A cross-national study. European Journal of Preventive Cardiology, DOI: 10.1177/2047487318766954

Hasanah, C., Naing, L., & Rahman, A. (2003). World Health Organization quality of life assessment: brief version in Bahasa Malaysia. Medical Journal of Malaysia, 58(1), 79-88.

Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., et al. (2014). National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1–executive summary. Journal of Clinical Lipidology, 8(5), 473-488.

Khoo, K. L., Page, M. M., Liew, Y. M., Defesche, J. C., & Watts, G. F. (2016). Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. Journal of Clinical Lipidology, 10(5), 1188-1194.

Lapadatu, I., & Morris, R. (2019). The relationship between stroke survivors’ perceived identity and mood, self-esteem and quality of life. Neuropsychological Rehabilitation, 29(2), 199-213.

Liddon, L., Kingerlee, R., & Barry, J. A. (2018). Gender differences in preferences for psychological treatment, coping strategies, and triggers to help‐seeking. British Journal of Clinical Psychology, 57(1), 42-58.

Megari, K. (2013). Quality of life in chronic disease patients. Health Psychology Research, 1(3).

Mortensen, G. L., Madsen, I. B., Kruse, C., & Bundgaard, H. (2016). Familial hypercholesterolaemia reduces the quality of life of patients not reaching treatment targets. Dan. Med. J, 63, A5224.

Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., et al. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. European Heart Journal, 34(45), 3478-3490.

Paasche-Orlow, M. K., & Wolf, M. S. (2007). The causal pathways linking health literacy to health outcomes. American Journal of Health Behavior, 31(1), S19-S26.

Powdthavee, N., Lekfuangfu, W. N., & Wooden, M. (2015). What's the good of education on our overall quality of life? A simultaneous equation model of education and life satisfaction for Australia. Journal of behavioral and experimental economics, 54, 10-21.

Rajadurai, J., Wan Ahmad, W. A., Nawawi, H., Choo, G. H., Ng, W. K., Mohd Ali, R., et al. (2018). Updates in the management of dyslipidaemia in the high and very high-risk individual for CV risk reduction. Medical Journal of Malaysia, 73(3), 154.

Sazlina, S., Zaiton, A., Afiah, M. N., & Hayati, K. (2012). Predictors of health-related quality of life in older people with non-communicable diseases attending three primary care clinics in Malaysia. The Journal of Nutrition, Health & Aging, 16(5), 498-502.

Stewart, D. E., & Yuen, T. (2011). A systematic review of resilience in the physically ill. Psychosomatics, 52(3), 199-209.

Tang, T. L.-P. (2007). Income and quality of life: Does the love of money make a difference? Journal of Business Ethics, 72(4), 375-393.

Vallejo-Vaz, A. J., De Marco, M., Stevens, C. A. T., Akram, A., Freiberger, T., Hovingh, G. K., et al. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277, 234-255. doi: 10.1016/j.atherosclerosis.2018.08.051

Varghese, M. J. (2014). Familial hypercholesterolemia: a review. Annals of Pediatric Cardiology, 7(2), 107.

Vodnala, D., Rubenfire, M., & Brook, R. D. (2012). Secondary causes of dyslipidemia. The American Journal of Cardiology, 110(6), 823-825.

Vuorio, A., Docherty, K. F., Humphries, S. E., Kuoppala, J., & Kovanen, P. T. (2013). Statin treatment of children with familial hypercholesterolemia–trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), 315-320.

Watts, G. F., Ding, P. Y., George, P., Hagger, M. S., Hu, M., Lin, J., et al. (2016). Translational research for improving the care of familial hypercholesterolemia: The “Ten Countries Study” and beyond. Journal of Atherosclerosis and Thrombosis, 23(8), 891-900.

Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., et al. (2015). Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 36(36), 2425-2437.

DOI: https://doi.org/10.21834/e-bpj.v4i10.1621


  • There are currently no refbacks.